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PrevIous stu les on panic disorder oruce et aL, 198b) have 
examined predicto's of relapse on a shan-term basis. This study 
. I~S igated predH'torc:: ')f relapse and Ir)" ~ ,..,,.m recove y' na i 
disorder treated with alprazolam or alprazolam plus cognitive 
behavior therapy (CST). Relapse was defined as a return to 
medication or other treatment after discontinuation. Logis ic 
regression analysis tested five variables derived from different 
conceptualizations of panic disorder etiology and treatment to 
determine if any predictors of relapse versus long-term recovery 
.ould be found Only +he change in Anxle y Sensitivity Index score 
rom baseline to posttaper was found to be significant (p 0.05, B = 
0.22, df =1, R = a25), This univanate model correctly classified 73 
percent of patlen outcomes at two to (our year followup This 
1:Jlng suggest th t f cu' on cognltl _ ....hange dU"'ll tr J tment 
ay help prevent re p. e Fut r resear h ~hould inel d c Jntr I 
ies to isolate the me .hanlsm 0 cognitive change. 
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Predictors of Relapse and Long-Term Recovery 
in Panic Disorder 
Background 
Panic disorder is an anxiety disorder in which victims 
experience attacks of symptoms such as a sudden feeling of 
, 
impending doom, heart palpitations, shortness of breath, dizziness, 
trembling, nausea, as well as other fearful sensations. These 
attacks seem to come out of nowhere and will last for several 
minutes. In order to be diagnosed with panic disorder, a patient must 
experience four attacks within a four-week period or one attack 
followed by at least one month of anxiety about experiencing another 
(Gitlin, 1990). According to the DSM-III-R (American Psychiatric 
Association, 1987), at least four of the following symptoms must be 
present to warrant a diagnosis of panic disorder: trembling, 
sweating, shortness of breath, depersonalization, fear of dying, 
chest pain, or heart palpitations, among others. Because patients 
fear having another attack, they will often avoid situations in which 
they have had previous attacks, as well as situations in which they 
fear another attack. This avoidance is termed agoraphobia. Panic 
disorder with agoraphobia (PDA) afflicts one to two percent of the 
U.S. population, with an average age of onset in young adulthood. The 
cause of this disorder is not yet entirely clear, although a 
combination of biological and cognitive features has been implicated 
(Gitlin,1990). 
Clark (1986) emphasizes the importance of catastrophic 
cognitive interpretations in the perpetuation of the disorder. 
According to Clark, panic attack victims misinterpret the benign 
•
 
physical responses associated with anxiety as being more dangerous 
than they really are. Thus, a person susceptible to panic disorder 
would interpret palpitations as a sign of an imminent heart attack. 
According to Clark's model of panic disorder, the victim can perceive 
both internal and externa.l stimuli as a threat. This perception will 
result in a state of apprehension, which is accompanied by various 
bodily sensations. If the victim interprets these sensations in a 
catastrophic fashion, the apprehension increases, w~lich in turn 
increases the bodily sensations. The cycle continues, finally 
culminating in a panic attack and escape or avoidance. In other 
words, according to Clark, a "fear of fear" is primarily responsible 
for the perpetuation of panic disorder (Figure 1). 
Insert Figure 1 about here. 
Two major types of treatment for panic disorder are medicinal 
and non-medicinal. Of the medicinal treatments, benzodiazepines 
such as alprazolam are the most frequently used. One advantage of 
benzodiazepines in the treatment of panic disorder is their rapid 
onset of action. In addition, the side effects of benzodiapine 
treatment are minimal in comparison to other types of medicinal 
intervention. (Ballenger et. aI., 1988). 
A major disadvantage of benzodiazepine treatment occurs 
when patients attempt to discontinue the drug. The patients 
are either unable to discontinue taking the drug, due to 
physical dependence, or they relapse soon after they stop medicinal 
treatment. Pecknold et. al. (1988), for example, found that 33 
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percent of patients are unable to discontinue the drug, and that 
patients who do discontinue benzodiazepine treatment have a 40 to 
75 percent acute relapse rate. 
A popular non-medicinal approach to treating PDA is through 
the use of cognitive-behavior therapy (CST). This method of 
treatment exposes patients to the interoceptive cues which often 
lead to a panic attack through Clark's "fear of fear" cycle. During 
CST, patients are instructed to engage in activities such as running 
in place, hyperventilation, etc., which elicit bodily sensations 
similar to those experienced during a panic attack. Exposure to these 
sensations extinguishes fear of the physical feelings associated 
with panic attacks and decreases the chance that these physical 
sensations will culminate in future panic attacks. Patients are also 
taught to manage anxiety and reduce catastrophic reactions to it. 
Those receiving CST have shown an 80 to 90 percent improvement 
rate out to a two year followup (Cerney et aI., 1987; Craske and 
Barlow,1990). 
Recently, cognitive-behavior therapy (CBT) has been integrated 
into benodiazepine therapy to see if it can aid discontinuation and 
prevent relapse. According to CBT formulations (e.g., Otto et aI., 
1992), the high rate of relapse is due to the patients' catastrophic 
cognitive interpretations. It is thought that the discontinuation 
process exposes patients to bodily sensations associated with panic 
during a time of increased anxiety and concern about the emergence 
of panic attacks. As a result, patients may begin the cycle of 
catastrophic interpretations posited by Clark (1986) and discussed 
above. 
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For example, Otto et. al.(1993) found that the use of CBT during 
the discontinuation of alprazolam significantly increased 
discontinuation rates from 25 percent via benzodiazepine treatment 
only to 77 percent in the combined treatment program. At three 
month follow-up, 59 percent of patients who received CBT 
successfully discontinued the benzodiazepine, lending preliminary 
support to the hypothesis that CBT may be effective in assisting 
discontinuation of alprazolam. 
A study by Spiegel et. al. (1994) found that adjunctive CBT can 
also prevent acute relapse. This study found that half of the patients 
who underwent alprazolam discontinuation without CBT relapsed and 
resumed alprazolam treatment within a six month follow-up period, 
whereas none of the patients treated with both alprazolam and CBT 
experienced relapse after six months. 
Finally, Hegel et. al. (1994) found that 76 percent of patients 
receiving the combined treatment remained medication free and 85 
percent were panic free after one year. A current study (Bond and 
Bruce, in progress), is examining the long term success of this 
combined treatment out to a two to four year follow-up. 
Based on the results of previous studies, then, it would appear 
that the combination of alprazolam and CBT has definite advantages 
over alprazolam treatment alone. However, while most of the 
research has focused on the outcome of panic disorder treatments, 
very few studies have examined predictors of relapse and recovery 
in panic disorder after treatment. Several possible predictors have 
been hypothesized, with some reflecting pharmacologic dependence 
conceptualizations of the disorder and others reflecting the types of 
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changes effected by CBT. A recent study investigated predictors of 
relapse and short-term recovery in panic disorder (Bruce et. aI., 
1995). In this study, change in Anxiety SensitiVity Index scores from 
baseline to posttaper assessments correctly classified in 85 
percent of the cases as to whether patients resumed alprazolam 
therapy at a three month follow up or did not. The present study 
investigated predictors of relapse and long-term recovery on a long­
term basis, at a two to four year follow-up. 
Method 
Participants 
Twenty two participants were recruited from patients who had 
participated in previous treatment studies at the University of 
Illinois College of Medicine at Peoria Anxiety Disorders Clinic 
(Spiegel et aI., 1994) and the Dartmouth Medical School Department 
of Psychiatry (Hegel et aI., 1994). Each participant was re-evaluated 
at a two to four year followup. In the original studies, all 
participants met DSM III R criteria for panic disorder with 
agoraphobia of at least six months duration. Diagnostic assessment 
was done with the Anxiety Disorders Interview Schedule-Revised 
(DiNardo and Barlow, 1988) and the Structured Clinical Interview for 
DSM III-R Personality Disorders (SCID-II) (Spitzer et. aI., 1990) 
(Appendix A). 
Patients were excluded if they met DSM III-R criteria for a 
major mood disorder, obsessive-compulsive disorder, or an organic 
mental syndrome. Those patients who were medically ill, pregnant, 
or breast-feeding, or who had a history of psychosis or drug abuse 
within the past year were also excluded, as were those who were 
n .. , !. C n I 
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undergoing psychotherapy; had had cognitive behavioral therapy for 
panic disorder in the past, or were taking medications other than 
alprazolam. 
To be included in this study, participants must have been 
taking between 1 and 10 mg per day of alprazolam as their only 
centrally acting medication. They must also have been free of 
unexpected panic attacks for at least one month (4 weeks). If 
necessary, participants underwent a period of alprazolam 
stabilization before beginning the study. Participants then 
underwent baseline assessment, maintenance and taper of 
alprazolam, posttaper assessment, and followup including two to 
four years posttaper. The study was approved by the Institutional 
Review Board of the College, and all participants gave informed 
consent before beginning the study. 
Treatments 
Pharmacotherapy. All participants (n = 22) underwent 
identical processes of alprazolam maintenance and taper. During the 
taper phase, the participant's medication was decreased every seven 
days (extendible to 14 days) until discontinuation was complete, or 
until the participant requested that the dose be reduced no further. 
Medication was handled by a psychiatrist who was blind to the 
participants' group assignments. The amount of contact participants 
in each group had with the psychiatrist was equivalent. 
Cognitive Behavior Therapy. In addition to the 
pharmacotherapy, some participants (n = 11) also received a form of 
cognitive behavior therapy developed by Barlow and Craske (Barlow 
and Craske, 1989; Craske and Barlow, 1990), which was 
• 
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administered individually in approximately 12 weekly sessions. 
Included in this treatment was education about panic disorder, 
training in slow, diaphragmatic breathing, cognitive restructuring, 
and interoceptive exposure (i.e., exposure to feared bodily sensations 
both in and out of the clinic). The breathing training and cognitive 
aspects were begun during alprazolam maintenance, while 
interoceptive exposure was begun approximately at the same time as 
the beginning of alprazolam taper, so that the drug taper was 
complete prior to the final cognitive behavior therapy session. 
Participants had no contact with the therapist after the 12 sessions 
were completed. 
Measures 
Assessments were conducted at baseline (after alprazolam 
stabilization), posttaper (two weeks after the last successfully 
completed alprazolam taper step), and at various followup points out 
to two to four years. These assessments consisted of self-report 
and clinician-rated measures of the major dimensions of PDA. 
Clinician ratings were made by a psychiatrist blind to participants' 
treatment protocol. 
Five measures were selected for predictive analysis that 
reflect different conceptualizations of relapse in panic disorder. 
Since one theory of panic disorder etiology posits that a cognitive 
change should affect discontinuation success (e.g., Clark, 1986), we 
chose to examine the baseline-to-posttaper change in AnXiety 
Sensitivity Index (ASI) scores. The ASI provides a measure of the 
patient' s fear of the bodily sensations related to panic. 
l' " 
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The second measure selected was withdrawal symptom 
severity, since one theory of panic disorder relapse holds that 
patients are unable to successfully discontinue medication due to 
the withdrawal symptoms they subsequently experience (Rickels et 
aI., 1993; Otto et aI., 1992). 
Two measures of patients' pretaper exposure to 
benzodiazepines were also assessed. The first was the patient' s 
stabilized alprazolam dose and the second was the duration of 
benzodiazepine use before taper. These measures were selected to 
re'flect the theory that perhaps it is the quantity or duration of 
benzodiazepine use which influences who relapses and who does not. 
Finally, we examined the baseline score on the Mobility 
Inventory for Agoraphobia as a determination of the severity of the 
illness (Chambless et aI., 1985). This inventory measures a patient's 
level of avoidance when alone. The selection of this measure 
re"flects the idea that the degree of phobic avoidance is a reliable 
indicator of the severity of panic disorder with agoraphobia and that 
pretreatment severity of the disorder may predict its relapse after 
treatment (Basoglu et aI., 1994). (See Appendices for copies of the 
Mobility Inventory for Agoraphobia and the Anxiety Sensitivity 
Index). 
Results 
Predictive Analysis 
Forward stepwise logistic regression (Hosmer and Lemeshow, 
1989) was used to determine if any variables correctly classified 
patients who relapsed versus those who successfUlly discontinued 
medication through the long-term followup. 
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The analyses of the measures were performed with an entry 
criterion of p < 0.05. Of the five variables analyzed, only the change 
in ASI score from baseline to posttaper was found to be significant 
at p < 0.05 (8 = 0.22, df = 1, R = 0.25). This univariate model 
correctly classified 73 percent of patient outcomes at a two to four 
year followup. 
Discussion 
This study found that the change in ASI scores from baseline to 
posttaper correctly classified 73 percent of the cases as to whether 
or not patients had relapsed at a two to four year followup. This 
finding supports Bruce et al. (1995), who found that a change in ASI 
scores from baseline to posttaper correctly classified patients' 
relapse in the short term (three month followup) 85 percent of the 
time. The present study, however, is the first to find this predictor 
significant in the long-term. 
This finding has considerable implications for treatment. If it ' 
is indeed possible to predict what types of patients will relapse, 
therapists may be able to adjust their treatment programs 
accordingly in order to prevent this relapse from occurring. More 
specifically, if the technique that actually changes the ASI score 
can be determined, therapists may rely more heavily on this 
technique than on solely pharmacological treatments. 
There are some problems with this study, however, which are 
worth noting. First, our use of a relatively small sample results in 
weaker statistical power, which means that generalization to the 
population of PDA patients should be done cautiously. In addition, it 
is possible that other predictors could emerge as a result of using a 
-r'l .. , .t­
larger sample size. Therefore, the results of this study should be 
considered preliminary findings needing replication. 
Second, this study did not control for the "active" elements in 
treatment accounting for the change in ASI. In other words, we found 
a significant correlation between a change in ASI score from 
baseline to posttaper, but such a correlation does not help us 
identify what it is in the treatment that is responsible for the 
change. 
This study offers several directions for future research. 
Because this study concentrated primarily on predictors of relapse 
and long-term recovery in a broad range of benzodiazepine users, 
(i.e., those receiving alprazolam alone and those receiving 
alprazolam plus CBT), future research could compare predictors 
between the two groups in order to elucidate differences between 
and determine what the components in the therapies that are 
responsible for relapse or recovery. A similar study with a larger 
sample would also help increase the generalization of the present 
findings to the larger population. Future studies should additionally 
aim to identify the specific techniques that are responsible for the 
change in ASI. Finally, other isolated variables based on additional 
conceptualizations of panic disorder could be compared more 
specifically in an attempt to develop a composite index of long term 
relapse and recovery in panic disorder. 
-n .. -., ,-1: ,.... ,. ,...,. .. ~,..., ..... .C' n 1 ~ 1 r 
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Appendix A: Screening Measures 
Due to copyright restrictions and time constraints, copies of 
the Anxiety Disorders Interview Schedule -- Revised and the 
Structured Clinical Interview for DSM III-R Personality Disorders 
were unavailable for this paper. 
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Appendix 8: The Mobility Inventory for Agoraphobia 
Name: Date: 
Please indicate the degree to which you avoid the following places or situations because of 
discomfort or anxiety. Rate your amount of avoidance when you are with a trusted 
companion and when you are alone. Do this by using the following scale. 
1. Never avoid 
2. Rarely avoid 
3. Avoid about half the time 
4. Avoid most of the time 
5. Always avoid 
(You may use numbers half-way between those listed when you think it is appropriate. 
For example, 3 1/2 or 4 1/2.) 
Write your score in the blanks for each situation or place under both conditions: when 
accompanied and when alone. Leave blank those situations that do not apply 
to you. 
When alone When accompanied 
PLACES 
-Theatres 
Supermarkets 
Classrooms 
Department stores 
Restaurants 
Museums 
Elevators 
Auditoriums or stadiums 
Parking garages 
High places 
Tell how high 
Enclosed spaces (e.g. tunnels) _ 
Open spaces: 
(A) Outside (e.g. fields, wide 
streets, courtyards) 
•
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(B) Inside (e.g. large rooms, 
lobbies) 
Riding In: 
(A) Buses 
(B) Trains 
(C)Subways 
(D) Airplanes 
(E) Boats 
Driving or riding in car: 
(A) At any time 
(B) On expressways _ 
SITUATIONS 
Standing in lines 
Crossing bridges 
Parties or social gatherings 
~---------
0.·,11,-1;,....1--,-... .... --. ".c T)r<ol....".-..,,...,,, "' ..... 
1--	 ­~J 
Walking on the street 
Staying at home alone N/A 
Being far away from home 
Other (specify) 
We define a panic attack as: 
(1)	 a high level of anxiety accompanied by 
(2) strong body reactions (heart palpitations, sweating,	 muscle tremors, dizziness, 
nausea) with 
(3) the temporary loss of the ability to plan, think, or reason and 
(4) the intense desire to escape or flee the situation. (Note, this is different from 
high anxiety or fear alone.) 
Please indicate the total number of panic attacks you have had in the last 7 days. 
• 
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Appendix C: Anxiety Sensitivity Index 
Name: 
Age: Date: Sex: M F 
Listed below are a number of statements describing a set of beliefs. Please read each 
statement carefully and, on the 0-5 scale given, indicate how much you think each 
statement is typical of vou. 
---0-----------1-----------2-----------3-----------4----------5 
Strongly Moderately Slightly Slightly Moderately Strongly 
Disagree Disagree Disagree Agree Agree Agree 
1. It is important to me not to appear nervous. 
2. When I cannot keep my mind on a task, I worry that I might be going crazy. 
3. It scares me when I feel 'shaky' (trembling). 
4. It scares me when I feel faint. 
5. It is important to me to stay in control of my emotions. 
-Drprl 11' f"r,.... r-,.C n ."1., ...... ,....,,.,, ,..,C' 
£	 ­
6. It scares me when my heart beats rapidly. 
7. It embarrasses me when my stomach growls. 
8. It scares me when I am nauseous. 
9.	 When I notice that my heart is beating rapidly, I worry that I might have a heart 
attack. 
10. It scares me when I become short of breath. 
11. When my stomach is upset, I worry that I might
 
be seriously ill.
 
12. It scares me when I am unable to keep my mind on a task. 
13. Other people notice when I feel shaky. 
14. Unusual body sensations scare me. 
15. When I am nervous, I worry that I might be mentally ill. 
16. It scares me when I am nervous. 
•
 
Figure Caption 
Figure 1. Clark's "fear of fear" cycle, one theory for the perpetuation 
of panic disorder. 
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